Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

To participate in this activity, please:

Log in Sign Up

The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and the burden of frequent intravenous administration. This 30-minute activity delves into the latest research presented at ISTH 2025, highlighting rebalancing agents and factor VIII mimetics. In addition to discussing details of each trial, Dr. von Drygalski shares her thoughts about its importance and relevance to clinical practice.

This content is also available as a podcast:  You may listen here.

Course Credit:

0.50 AAPA Category I CME Credit
0.50 ACPE Contact Hours
0.50 AMA PRA Category 1 CreditsTM
0.50 ANCC Contact Hours
0.50 CA-BRN Contact Hours

Dates:

Opens: 2025-08-13
Closes: 2026-08-13

Target Audience:

This activity was developed for hematologists, hematology nurse practitioners, hematology physician associates, pharmacists, and other clinicians involved in the management of patients with hemophilia.

This activity is supported by an educational grant from Novo Nordisk, Inc.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 hours AAPA Category 1 CME credits. Approval is valid until August 13, 2026. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.5 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Zahra Mahmoudjafari, PharmD, MBA, BCOP (Medical Writer)

Advisory Board: BMS, Genentech, Kite, Pfizer, Sanofi


Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Annette von Drygalski, MD, PharmD, RMSK headshot

    Annette von Drygalski, MD, PharmD, RMSK

    Professor of Clinical Medicine
    Director, Center for Bleeding and Clotting Disorders
    Associate Director, Center of Excellence for Hereditary Hemorrhagic Telangiectasia
    Program Director, Coagulation Medicine Fellowship
    Associate Program Director, Hematology Fellowship
    University of California, San Diego
    San Diego, California

Learning Objectives

  • Evaluate the safety and efficacy of rebalancing agents and factor VIII mimetics in patients with hemophilia A or B with or without inhibitors.
  • Assess management considerations of rebalancing agents and factor VIII mimetics for the treatment of patients with hemophilia.
  • Develop treatment plans for patients with hemophilia using evidence-based recommendations.

Faculty Disclosures

Annette von Drygalski, MD, PharmD, RMSK

Advisory Board: BioMarin, CSL-Behring, Genentech, Novo Nordisk, Sanofi, Sparx Therapeutics, Takeda

Consultant: Sobi